Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations
Antimicrobial Agents and Chemotherapy · 06.08.2025 · 69 (8)
DOI: 10.1128/aac.01063-24 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.08.2025. Verfasst von Christine J Kubin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Acinetobacter Infections. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 228 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Antimicrobial resistance poses a major challenge in the treatment of Acinetobacter baumannii. Acinetobacter spp. are intrinsically resistant to a number of commonly used antibiotics. Over the past 3 years, the European and American Professional Societies have provided important guidelines on the treatment options for carbapenem-resistant A. baumannii (CRAB). Here, we review the recent literature on combination regimens for CRAB as well as carbapenem-susceptible A. baumannii infections. We discuss the strengths and weaknesses of various agents used in combination, depending on the site of infection and their pharmacokinetic properties. Consistent with the 2024 Infectious Diseases of America (IDSA) update, sulbactam-durlobactam, in combination with background carbapenem therapy, remains the combination with the greatest reduction in mortality for pulmonary infections and has promising outcomes in bloodstream infections with CRAB. Sulbactam-based combination therapy remains an ideal part of targeted strategies and has been shown to be associated with reduced mortality. Certain agents have been highlighted in the literature for suboptimal outcomes, primarily pulmonary infections treated with cefiderocol, tigecycline, and eravacycline. Studies including non-pulmonary infections, specifically bacteremia and central nervous system (CNS) infections, are overall limited to case series and subgroup analyses. Important areas for further research include breakpoint evaluations for eravacycline and minocycline as well as subclinical resistance in cefiderocol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
- Department of Pharmacy, NewYork-Presbyterian Hospital, New York, New York, USA.
ORCID-Profile: Christine J Kubin, Christopher Garzia, Anne-Catrin Uhlemann
Förderung
- NIH HHS
- NIAID NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
Zitieren
APA
Kubin, C. J., Garzia, C., & Uhlemann, A. C. (2025). Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations. Antimicrobial Agents and Chemotherapy, 69(8). https://doi.org/10.1128/aac.01063-24
Vancouver
Kubin CJ, Garzia C, Uhlemann AC. Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations. Antimicrobial Agents and Chemotherapy. 2025;69(8). doi:10.1128/aac.01063-24
BibTeX
@article{Kubin2025,
author = {Kubin, Christine J and Garzia, Christopher and Uhlemann, Anne-Catrin},
title = {Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {8},
doi = {10.1128/aac.01063-24}
}
EUVIMED